Quanterix Corporation (QTRX) AI Stock Analysis

Quanterix Corporation develops and commercializes digital immunoassay platforms designed to advance precision health across North America, Europe, the Middle East, Africa, and the Asia Pacific. Its core platforms include the automated HD-X instrument for multiplex protein detection, the SR-X instrument integrating Simoa detection technology, and the SP-X instrument using Simoa planar array technology for chemiluminescent immunoassays. The company complements its instruments with assay kits, consumables, reagents, and contract research services such as custom solutions and homebrew assay development. It serves academic laboratories, government research facilities, pharmaceutical companies, biotechnology firms, and contract research organizations in fields such as neurology, oncology, cardiology, infectious diseases, and inflammation.

Between FY2021 and FY2025, Quanterix's revenue rose from $110.6M to $138.7M, achieving a 5-year revenue CAGR of 9.9% from FY2020 to FY2025. Annual growth fluctuated, posting 28.0% in FY2021, -4.6% in FY2022, 14.8% in FY2023, 11.8% in FY2024, and 2.4% in FY2025. Gross margin declined from 55.8% in FY2021 to 46.7% in FY2025, while operating margin deteriorated from -53.0% to -79.2%. Net income was -$107.2M in FY2025, widening from -$38.5M in FY2024. For the latest quarter ending June 30, 2026, quarterly revenue growth accelerated to 34.4% year-over-year, lifting trailing twelve month revenue to $153.4M with a profit margin of -80.2%.

As of June 30, 2026, Quanterix held $93.5M in cash and short-term investments against $33.4M in total debt, yielding a net cash position of $60.1M. The company maintains a current ratio of 3.40 and a debt-to-equity ratio of 0.14 against shareholders' equity of $237.2M. Free cash flow for FY2025 was -$79.8M, weighed down by operating cash flow of -$77.2M and capital expenditures of $2.6M. In addition, the company's share count increased by 28.0% over the five-year period.

At a market cap of $135.7M and an enterprise value of $89.3M, Quanterix trades at a price-to-sales multiple of 0.9x and an EV-to-revenue ratio of 0.6x. These metrics place it below the median of its US-listed Healthcare peers, which trade at a price-to-sales multiple of 4.1x and an EV-to-EBITDA multiple of 12.0x. The company's price-to-book ratio is 0.6x. Over the past year, the stock fell 51.8%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year period, the stock dropped 94.4% compared to an 83.0% gain for the benchmark.

Quanterix is currently covered by 3 analysts, all rating the stock as a Hold. The mean price target is $3.17, representing an upside of 10.3% over the last close of $2.87 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.23 on revenue of $143.4M. For the following fiscal year, 1 analyst projects revenue of $157.6M and an EPS of -$1.36. Quanterix beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Quanterix Corporation (QTRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QTRX income statement, QTRX balance sheet, QTRX key metrics, QTRX analyst forecast, QTRX chart. See the QTRX stock overview for the latest quote and news.